USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: PHOENICIA BIOSCIENCES, INC.
Address: 45 Beaver Rd
WESTON, MA 02493-1017
Located in HUBZone: No
Woman-Owned: Yes
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $288,895.00 1
STTR Phase I $1,636,697.00 5

Award List:

Development of an Oncogene-Targeted Therapeutic

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: HHS
Research Institution: BOSTON UNIVERSITY MEDICAL CAMPUS
Principal Investigator: Douglas V. Faller
Award Amount: $271,227.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The concept of targeting cancer therapeutics towards specific mutations or abnormalities in tumor cells which are not found in normal tissues has the potential advantages of high selectivity for the tumor and correspond ingly low secondary toxicities. At least… More

Oral Agents to Stimulate Neutrophil Production

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: Boston University
Principal Investigator: Susan P. Perrine – 617-638-5639
Award Amount: $350,566.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Phoenicia Biosciences, Inc. scientists have discovered a small family of low MW compounds (short-chain fatty acid derivatives (SCFADs) - designated Hemokines ) that stimulate proliferation of human hematopoietic progenitors, multi-lineage-hematopoietic cell… More

Virus-Targeted Therapy for Malignancies

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Susan P. Perrine – 617-638-5639
Award Amount: $288,895.00
Abstract:
DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human malignancies for which there are presently few effective treatments. Lymphoid malignancies caused by, or associated with, Epstein-Barr virus include Burkitt's lymphoma, T/NK lymphomas, some T-… More

in vivo Studies of Clinical Stage Globin Modulators

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
Principal Investigator: Susan P. Perrine – 617-638-5639
Award Amount: $304,344.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Inherited disorders which decrease production or alter structure of the 2-chain of hemoglobin A (2-thalassemias or sickle cell disease) are among the most common monogenic diseases in the world, afflicting millions worldwide, and are designated by WHO as a global… More

Next Generation Therapeutics for Hemoglobinopathies

Award Year / Program / Phase: 2012 / STTR / Phase I
Agency: HHS
Research Institution: BOSTON UNIVERSITY
Principal Investigator: Susan P. Perrine – 617-638-5639
Award Amount: $491,254.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Sickle cell disease and 2-thalassemias are mankind's most common hereditary monogenic diseases, comprise a major global health burden, and cost the US healthcare system gt 1 billion annually. Patients have chronic disabling morbidity and early mortality.… More

Topical Therapeutic to Promote Healing of Chronic Wounds

Award Year / Program / Phase: 2013 / STTR / Phase I
Agency: HHS
Research Institution: BOSTON UNIVERSITY
Principal Investigator: Susan P. Perrine – 617-638-5639
Award Amount: $219,306.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is defined as a wound that does not show signs of significant healing, or progresses, after use of… More